CEO says he'll lower price of $750-a-pill antibiotic After Criticism

Publish date:
Social count:

Martin Shkreli, chief executive officer of Turing Pharmaceuticals AG, said he would lower the price of the drug Daraprim after being criticized for boosting it 50-fold to $750 a pill.

This drug is is the standard of care for treating a life-threatening parasitic infection. Now, this medicine helps those with weak immune systems, like people suffering from AIDS or the effects of chemotherapy, fight off a dangerous parasite that can cause brain infections and blindness. It’s also used both to treat and prevent malaria.

Shkreli got tons of backlash from the web and from presidential candidates, Hillary Clinton and Bernie Sanders after he tried to defend his decision in this video.


But, Tuesday in a news interview with ABC NEWS, he'd said he's lower the price:

"We have agreed to lower the price of Daraprim to a point that is more affordable," Shkreli said Tuesday in an interview with ABC News. He didn't say what the new price would be.

Turing acquired an older antibiotic drug, Daraprim, in August and soon after that raised the price to $750 a pill from $13.50. Shkreli had defended the price increase for Daraprim, calling it a bargain even at the higher price in an interview Monday.

We'll have to wait and see what price he finally lowers it to, soon.